Table 1.
Selection of inflammatory cytokines elevated in plasmas of MPN patients of all disease stages.
| 1st Author | Pardanani (42) | Tefferi (43) | Vaidya (44) | Kalota (45) | Pourcelot (46) | Cacemiro (47) | Fisher (48) | Fowles (41) |
| journal | Am J Hematol | J Clin Oncol | Am J Hematol | Clin Cancer Res | Exp Hematol | Hematol Transfus Cell Ther | Leukemia | Leukemia |
| year | 2011 | 2011 | 2012 | 2013 | 2014 | 2019 | 2019 | 2019 |
| EGF | ns | ns | HD > PV; PMF > PV |
- | - | - | - | - |
| b-FGF | ns | ns | PMF > PV | - | - | - | - | - |
| G-CSF | ns | PMF > HD | ns | MF > HD; PV > HD |
- | - | - | ns |
| GM-CSF | MF > HD | ns | PV > HD; PV > PMF |
MF > HD; PV > HD |
PV > HD; ET > HD |
MPN > HD; PV > ET |
ns | - |
| HGF | MF > HD | PMF > HD | PV > HD | - | PV > HD; ET > HD |
- | - | - |
| IFN-α | ns | PMF > HD | PMF > PV | MF > HD; PV > HD |
- | MPN > HD | - | - |
| IFN-γ | MF > HD | HD > PMF | PV > PMF | MF > HD; PV > HD |
PV > HD; ET > HD |
PMF > ET | ns | PV > HD |
| IL-4 | MF > HD | ns | ns | - | PV > HD; ET > HD |
MPN > HD; PV > ET |
ns | - |
| IL-5 | ns | ns | PV > HD | - | - | MPN > HD | ns | - |
| IL-6 | MF > HD | PMF > HD | PV > HD | MF > HD; PV > HD |
PV > HD; ET > HD |
MPN > HD | MF > HD | PV > HD |
| IL-8 | MF > HD | PMF > HD | PV > HD | - | PV > HD; ET > HD |
- | - | ns |
| IL-10 | MF > HD | PMF > HD | PMF > PV | - | PV > HD; ET > HD |
MPN > HD | MF > HD | - |
| IL-12 | MF > HD | PMF > HD | PV > HD; PMF > PV |
- | PV > HD; ET > HD |
MPN > HD; PMF > ET; PV > ET |
ns | - |
| IL-13 | MF > HD | PMF > HD | PV > HD | - | - | - | ns | - |
| IL-15 | MF > HD | PMF > HD | PV > HD | - | - | - | ns | - |
| IL-16 | ns | - | - | - | - | - | MF > HD | - |
| IL-17 | MF > HD | ns | ns | - | - | PMF > HD; PMF > ET |
ns | - |
| IL-1RA | MF > HD | PMF > HD | PV > HD; PMF > PV |
- | - | - | - | - |
| IL-1β | MF > HD | PMF > HD | PMF > PV | - | ns | MPN > HD | ns | - |
| IP-10 | MF > HD | PMF > HD | PV > HD; PV > PMF |
- | - | PMF > ET | ns | PV > HD |
| MCP-1 | MF > HD | PMF > HD | PV > HD | - | PV > HD; ET > HD |
ns | ns | - |
| MIG | MF > HD | PMF > HD | PV > HD; PV > PMF |
- | - | - | - | - |
| MIP-1α | MF > HD | PMF > HD | PV > HD; PV > PMF |
- | - | MPN > HD | ns | PV > HD |
| MIP-1β | MF > HD | PMF > HD | PV > HD; PV > PMF |
MF > HD; PV > HD |
- | PV > HD; ET > HD |
ns | - |
| RANTES | MF > HD | ns | HD > PV; PMF > PV |
MF > HD; PV > HD |
- | ET > HD; PV > ET |
- | - |
| sIL-2R | MF > HD | PMF > HD | PMF > PV | - | - | - | - | PV > HD |
| TNFRII | - | - | - | - | - | - | - | - |
| TNF-α | MF > HD | PMF > HD | ns | MF > HD; PV > HD |
PV > HD; ET > HD |
MPN > HD | ns | PV > HD |
| VEGF | MF > HD | PMF > HD | PV > HD; PV > PMF |
- | PV > HD; ET > HD |
- | MF > HD | ns |
MF, myelofibrosis; PMF, primary myelofibrosis; HD, healthy donor; PV, polycythemia vera; ET, essential thrombocythemia; MPN, myeloproliferative neoplasms; ns, no significant differences between sample types; “>“, first sample type is significantly elevated compared to second sample type; “-”, not in assay.